Close Menu

N-of-One

With the acquisition, Qiagen will integrate N-of-One’s MarkerMine database into its core technology to help customers design new, targeted therapies.

Sunquest and N-of-One are aiming to help pathologists create actionable, patient-specific genetic reports from NGS panels.

N-of-One will help Agena interpret cancer genomic data generated by its MassArray system as part of a recently launched reporting network.

One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.

N-of-One will interpret data from HemeSeq profiles for acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and other cancers.

N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.

N-of-One will use the funds to develop new oncology clinical decision support solutions, and to expand its sales and marketing efforts.

N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.

N-of-One will provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.

N-of-One will provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.